

October 28, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 28th October, 2025

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (28/10/2025):

1. Financial Results:

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and half year ended 30/09/2025 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations"), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records and for uploading in your website. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

2. Approved the appointment of Mr. Chan Sing En as the Independent Director (DIN: 11300541) with effect from 28th October 2025. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure-2**.
3. Recommended the appointment of Tan Sri Dato' Dr. Syed Jalaludin as the Independent Director (DIN: 11336135) with effect from the date of approval of the Shareholders. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure-3**.

4. Considered & approved the Postal Ballot Notice to be issued to Shareholders for obtaining their consent relating to Appointment of Independent Directors
5. Considered & approved the appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary as Scrutinizer of the Postal Ballot, to scrutinize the e-voting and remote e-voting process in a fair and transparent manner;

The Board Meeting commenced at 06:00 PM (IST) and concluded at 6:45 PM (IST)

Please take on record.

Thanking You,

Yours Truly,

Thanking You,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V

COMPANY SECRETARY AND COMPLIANCE OFFICER



FISCHER MEDICAL VENTURES LIMITED (formerly known as Fischer Chemic Limited)
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Nadupuru, Visakhapatnam, Andhra Pradesh, India, 530044

Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India

Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.09.2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

Sl. NO	PARTICULARS	STANDALONE						CONSOLIDATED						
		Quarter Ended			Half Year Ended			Quarter Ended			Half Year Ended			Year Ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
I	Revenue From Operations	742.69	454.23	-	1,196.92	-	521.97	8,630.53	2,344.47	3,965.53	10,975.00	4,977.60	11,069.87	
II	Other Income	143.46	80.40	81.96	223.86	194.19	345.70	248.14	746.64	22.35	994.78	96.52	149.20	
III	Total Income (I + II)	886.15	534.63	81.96	1,420.78	194.19	867.67	8,878.67	3,091.11	3,987.88	11,969.78	5,074.12	11,219.07	
IV	Expenses													
	Cost of Materials Consumed	-	-	-	-	-	-	14.89	-	-	14.89	-	-	
	Purchase of Stock-In-Trade	463.47	318.59	6.50	782.06	6.50	461.06	1,119.76	758.01	4,086.33	1,877.76	5,838.16	9,528.18	
	Changes In Inventories of Finished Goods, Work-In-Progress And Stock-In-Trade	-	-	(6.50)	-	(6.50)	(6.50)	133.52	496.32	(473.77)	629.84	(1,364.17)	(369.22)	
	Employee Benefits Expense	45.46	41.75	4.18	87.22	6.71	12.84	374.75	315.77	50.60	690.53	89.91	258.13	
	Direct Expenses	-	-	-	-	-	-	4,895.35	22.09	-	4,917.45	-	-	
	Finance Costs	111.77	130.88	-	242.65	-	13.17	91.87	66.99	4.86	158.86	17.36	46.68	
	Depreciation and Amortisation Expenses	8.16	8.16	0.05	16.32	0.10	12.72	51.37	76.97	28.81	128.34	56.54	163.28	
	Other Expenses	119.47	56.81	31.44	176.26	40.14	278.30	466.75	326.27	252.98	793.02	381.92	1,321.11	
	Total Expenses	748.33	556.19	35.67	1,304.51	46.95	771.59	7,148.25	2,062.42	3,949.81	9,210.68	5,019.73	10,948.16	
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	137.82	(21.56)	46.29	116.27	147.23	96.08	1,730.41	1,028.68	38.07	2,759.09	54.39	270.92	
VI	Share of Profit / (Loss) of Associates	-	-	-	-	-	-	4.22	(11.15)	(17.05)	(15.37)	(25.77)	(48.65)	
VII	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-	
VIII	Profit / (Loss) Before Tax (V - VI)	137.82	(21.56)	46.29	116.27	147.23	96.08	1,726.19	1,017.53	21.02	2,743.73	28.62	222.27	
IX	Tax Expense													
	Current Tax	-	-	5.00	-	12.00	(52.00)	(275.14)	(441.62)	5.00	(716.76)	(12.00)	(107.95)	
	Deferred Tax Expenses	(54.05)	(39.38)	(0.01)	(93.44)	0.03	27.64	(61.47)	(75.09)	3.31	(136.57)	1.00	11.87	
	Tax pertaining to Previous year	-	-	-	-	-	(5.40)	-	-	-	-	-	(5.40)	
	Reversal of Excess Provision / Provision For Taxation Relating To Earlier Years	-	-	-	-	-	-	-	-	-	-	-	-	
X	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	83.77	(60.94)	51.28	22.83	135.20	66.32	1,389.58	500.82	29.33	1,890.40	17.62	120.79	
XI	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	
XII	Tax Expense of Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	
XIII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-	
XIV	Profit / (Loss) For The Period (IX + XII)	83.77	(60.94)	51.28	22.83	135.20	66.32	1,389.58	500.82	29.33	1,890.40	17.62	120.79	
XV	Other Comprehensive Income													
	Items That Will Not Be Reclassified To Profit / (Loss)													
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	6.32	-	-	6.32	-	(0.78)	
	(ii) Income Tax Relating on Above	-	-	-	-	-	-	-	-	-	-	-	-	
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	
	Other Comprehensive Income - Total	-	-	-	-	-	-	6.32	-	-	6.32	-	(0.78)	
XVI	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	83.77	(60.94)	51.28	22.83	135.20	66.32	1,395.91	500.82	29.33	1,896.73	17.62	120.01	
XVII	Paid Up Equity Share Capital (Face Value Re.1/-) (Refer Note.3)	6,485.15	6,485.15	5,350.00	6,485.15	5,350.00	6,380.15	6,485.15	6,485.15	5,350.00	6,485.15	5,350.00	6,380.15	
XVIII							24,166.26						24,350.14	
XIX	Earnings Per Share (EPS)													
	(a) Basic EPS From Continuing Operations (In Rs.)	0.13	(0.09)	0.10	0.04	0.25	0.05	2.15	0.77	0.05	2.92	0.03	0.22	
	(b) Basic EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-	
	(c) Diluted EPS From Continuing Operations (In Rs.)	0.13	(0.09)	0.09	0.03	0.25	0.04	2.11	0.76	0.05	2.87	0.03	0.22	
	(d) Diluted EPS From Discontinued Operations (In Rs.)	-	-	-	-	-	-	-	-	-	-	-	-	

1 These unaudited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements".

2 The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 28th October 2025

3 On 28th July, 2025, the Board approved the sub division of Equity shares of Rs 10/- into 10 equity shares of Re 1/- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August 2025. Effective from the record date of 12th September 2025, the authorized and Paid up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability

4 Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification

5 The above statement has been prepared to the extent applicable, in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company

6 The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company

7 The Statutory Auditor of the Company have carried out a Limited Review of the above Standalone and Consolidated Financial Results for the Quarter / Half Year ended 30.09.2025 and their report was placed before the Board

8 The above is an extract of the detailed format of Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Half Year ended Unaudited Standalone and Consolidated Financial Results are available in the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and Company's website at www.fischermv.com

// BY ORDER OF THE BOARD //



For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661


Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended 30th September 2025 and for the year to date results for the period 1 April 2025 to 30 September 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

1. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Bilimoria Mehta & Co,
Chartered Accountants
FRN.: 101490W**



CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: 28-10-2025

UDIN: 25165824BMIINO1663

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

Standalone Balance Sheet as at September 30th, 2025

(In Lakhs)

Particulars	As At 30th Sep 2025	As At 31st Mar 2025
Assets		
(1) Non-Current Assets		
Property, plant and equipment	0.27	0.38
ROU Asset	51.34	67.55
Deferred Tax Asset (Net)		27.63
Financial Assets		
(i) Investments	30,356.12	29,435.94
(ii) Other Financial asset	3,956.34	3,501.90
Other Non Current Assets	62.30	62.30
Total Non-Current Assets	34,426.37	33,095.69
(2) Current assets		
(a) Inventories	6.50	6.50
(b) Financial assets		
(i) Trade receivables	2,134.78	1,707.68
(ii) Cash and cash equivalents	825.41	28.71
(iii) Other Current Financial Asset	164.81	710.60
(c) Current Tax Asset (Net)		
(d) Other Current Assets	508.50	301.25
Total Current Assets	3,640.00	2,754.74
Total Assets	38,066.37	35,850.44
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,485.15	6,380.15
(b) Other Equity	27,367.88	27,188.35
Reserve & Surplus	24,432.94	24,166.26
(c) Money received against share warrants	2,934.95	3,022.10
Total Equity	33,853.04	33,568.51
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability	65.81	
(b) Financial Liabilities		
(i) Lease Liabilities	1,891.52	1,569.66
(ii) Borrowings		
(c) Other Non Current Liabilities	-	-
(d) Provisions	5.28	
Total Non-Current Liabilities	1,962.60	1,569.66
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	1,774.03	
(ii) Lease Liabilities	28.94	637.93
(iii) Trade payables		
total outstanding dues of micro enterprises and small enterprises	0.15	2.05
total outstanding dues of creditors other than micro enterprises and small enterprises	279.57	37.36
(iv) Other Financial liabilities	137.89	13.83
(b) Short Term Provisions	0.50	
(c) Other Current Liabilities	12.07	
(d) Current Tax Liabilities	17.57	21.10
Total Current Liabilities	2,250.73	712.27
Total Equity and Liabilities	38,066.37	35,850.44



For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)					
CIN : L86900AP1993PLC118162					
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September 2025					
(Amount in lakhs)					
Particulars	Quarter Ended			Half Year ended	
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024
I) Revenue From Operations	742.69	454.23		1,196.92	
II) Other Income	143.46	80.40	81.96	223.86	194.19
III) Total Income (I+II)	886.15	534.63	81.96	1,420.78	194.19
IV) Expenses :					
Purchase of Traded Goods	463.47	318.59	6.50	782.06	6.50
Changes in inventories of finished goods, by-products and work in progress	-		-6.50	-	-6.50
Employee Benefit expenses	45.46	41.75	4.18	87.22	6.71
Depreciation and Amortization Expenses	8.16	8.16	0.05	16.32	0.10
Finance Cost	111.77	130.88	-	242.65	
Other Expenses	119.47	56.80	31.44	176.26	40.14
Total Expenses (IV)	748.33	556.18	35.67	1,304.51	46.95
V) Profit (Loss) Before exceptional and tax (III-IV)	137.82	(21.55)	46.29	116.27	147.23
Profit before tax (V-VI)	137.82	(21.55)	46.29	116.27	147.23
VIII) Tax Expenses					
i) Current Tax	-	-	5.00	-	(12.00)
ii) Deferred Tax	(54.05)	(39.38)	(0.01)	(93.44)	(0.03)
IX) Profit (Loss) from Continuing Operations (VII-VIII)	83.77	(60.94)	51.28	22.83	135.20
X) Profit (Loss) from Discontinuing Operations	-	-	-	-	-
XI) Tax Expenses for Discontinuing Operations	-	-	-	-	-
XII) Profit (Loss) from Discontinuing Operations (After Tax) (X-XI)	-	-	-	-	-
XIII) Profit (Loss) for the period (XI+XII)	83.77	(60.94)	51.28	22.83	135.20
XIV) Other Comprehensive income;					
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (XIII-XIV)	83.77	(60.94)	51.28	22.83	135.20
XVI) Earnings per Equity Shares					
1) Basic	0.13	(0.09)	0.10	0.04	0.25
2) Diluted	0.13	(0.09)	0.09	0.03	0.25



For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)
STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. In Lakhs)

PARTICULARS	FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2025	FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2024
Cash Flow From Operating Activities		
Net Profit Before Tax	116.27	147.23
Adjustments for:		
Depreciation	16.32	0.10
Interest Income	(223.86)	-
Interest & Finance Charges	242.65	-
Operating Profit Before Working Capital Changes	151.38	147.33
Adjustments for:		
Changes in Other Current Asset	(210.54)	(9.70)
Changes in Trade Receivables	(427.10)	140.31
Changes in Inventories	-	(6.50)
Changes in Trade Payables	240.32	(1,199.13)
Changes in Other Financial Liabilities	124.06	1.77
Changes in Other Financial Assets	91.36	0.08
Changes on account of Acquisition		
Changes in Provisions	5.77	-
	(12.68)	(931.06)
Less:- Direct Taxes Paid		
Current Tax Paid	-	(18.94)
A Net Cash from Operating Activities	(12.68)	(950.00)
Cash Flow from Investing Activities		
Purchase of Property, Plant and Equipment and ROU Asset	-	-
Sale of of Property, Plant and Equipment		
Investments	(920.18)	(333.37)
Loan and advances given	-	1,425.29
Dividend Income		
B Net Cash Used in Investing Activities	(696.32)	1,091.92
Cash Flow from Financing Activities		
Proceeds from issuance of Share Capital and Share Premium	261.45	-
Proceeds from Borrowings	1,774.03	-
Changes in Lease liability	(287.13)	-
Interest & Finance Charges	(242.65)	-
C Net Cash from Financing Activities	1,505.70	-
D Net Increase/(Decrease) in Cash & Cash Equivalents(A+B+C)	796.70	141.92
E Opening Cash & Cash Equivalents (Cash and Bank Balances)	28.71	0.38
F Effect of exchange rates on cash and cash equivalents	-	
G Closing Cash & Cash Equivalents (D+E)	825.41	142.30



For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)


1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 September 2025 and consolidated year to date results for the period 1 April 2025, to 30 September 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs 46,765.27 Lakhs as at 30 September 2025, and year-to-date total revenues of Rs 11,969.78 lakhs and year-to-date total comprehensive loss of Rs 1,920.71 lakhs, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W



CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date:
UDIN: 25165824BMMIINP3721

ANNEXURE-1

List of Entities included in the statement:

Sr no	Particulars	Stakes	Status
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer Medical Ventures Limited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
10	FMV Global Innovation PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

Consolidated Balance Sheet as at September 30th, 2025

Particulars	30th September 2025	31st March 2025
Assets		
(1) Non-Current Assets		
Property, Plant & Equipment	2,257.69	1,442.51
CWIP	190.04	111.12
ROU Asset	355.44	417.90
Goodwill	527.70	527.70
Financial Assets	-	-
(i) Investments	12,100.71	1,077.18
(ii) Other Financial asset	4,073.54	5,530.94
Deferred Tax Asset (Net)	4.82	38.74
Other Non Current Assets	959.51	62.30
Total Non-Current Assets	20,469.45	9,208.38
(2) Current assets	-	-
(a) Inventories	524.84	916.37
(b) Financial assets	-	-
(i) Trade receivables	16,226.74	7,606.63
(ii) Cash and cash equivalents	1,239.56	10,426.28
(iii) Bank balances other than cash and cash equivalents	3,047.40	14,709.38
(iv) Other Current Financial Asset	4,520.81	2,395.95
(c) Current Tax Asset(Net)	-	-
(d) Other Current Assets	736.47	474.05
Total Current Assets	26,295.82	36,528.65
Total Assets	46,765.27	45,737.04
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,484.67	6,380.15
(b) Other Equity	29,506.62	27,372.23
(c) Non Controlling Interest	64.07	34.15
Total Equity	36,055.36	33,786.54
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability	141.91	39.27
(b) Financial Liabilities	-	-
(i) Lease Liabilities	2,060.87	1,694.35
(ii) Borrowings	673.98	26.25
(iii) Other Financial Liabilities	-	-
(c) Provisions	8.66	8.51
Total Non-Current Liabilities	2,885.41	1,768.38
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	853.36	6,013.87
(ii) Lease Liabilities	112.64	802.76
(iii) Trade payables	-	-
total outstanding dues of micro enterprises and small enterprises	49.20	1,472.65
total outstanding dues of creditors other than micro enterprises and small enterprises	4,226.72	592.84
(iv) Other Financial liabilities	209.99	54.38
(b) Short Term Provisions	801.87	58.90
(c) Other Current Liabilities	1,553.14	1,165.62
(d) Current Tax Liabilities	17.57	21.10
Total Current Liabilities	7,824.50	10,182.11
Total Equity and Liabilities	46,765.27	45,737.03

For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)



[Signature]

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)
CIN : L86900AP1993PLC118162
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September
2025 **(Amount in lakhs)**

Particulars	Quarter Ended			Half Year ended	
	30th September 2025	30th June 2025	30th September 2024	30th September 2025	30th September 2024
			Unaudited	Unaudited	Unaudited
I) Revenue From Operations	8,630.53	2,344.47	3,965.53	10,975.00	4,977.60
II) Other Income	248.14	746.64	22.35	994.78	96.52
III) Total Income (I+II)	8,878.67	3,091.11	3,987.87	11,969.78	5,074.12
IV) Expenses :					
Cost of Material Consumed	14.89			14.89	
Purchase of Traded Goods	1,119.76	758.01	4,086.33	1,877.76	5,838.16
Changes in inventories of finished goods, by-products and work in progress	133.52	496.32	(473.77)	629.84	(1,364.17)
Direct Expenses	4,895.35	22.09		4,917.45	
Employee Benefit expenses	374.75	315.77	50.60	690.53	89.91
Depreciation and Amortization Expenses	51.37	76.97	28.81	128.34	56.54
Finance Cost	91.87	66.99	4.86	158.86	17.36
Other Expenses	466.75	326.27	252.98	793.02	381.92
Total Expenses (IV)	7,148.25	2,062.43	3,949.81	9,210.68	5,019.73
V) Profit (Loss) Before exceptional and tax (III-IV)	1,730.41	1,028.68	38.07	2,759.10	54.39
VII) Share of Profit/Loss from Associate					
- The Therapy Platform Pte Ltd	(4.15)	0.11	(6.22)	(4.04)	-9.83
- Bluesim tech pte ltd FS	(0.07)	(11.26)	(10.83)	(11.33)	-15.93
Profit/(loss) before exceptional items and tax (VII + VIII)	1,726.20	1,017.53	21.02	2,743.73	28.62
VI) Exceptional Items			-	-	-
Profit before tax (V-VI)	1,726.20	1,017.53	21.02	2,743.73	28.62
VIII) Tax Expenses					
i) Current Tax	(275.14)	(441.62)	5.00	(716.76)	(12.00)
ii) Deferred Tax	(61.47)	(75.09)	3.31	(136.57)	1.00
iii) Tax pertaining to previous year		-	-		
IX) Profit (Loss) from Continuing Operations (VII-VIII)	1,389.58	500.82	29.33	1,890.41	17.62
XIII) Profit (Loss) for the period (XI+XII)	1,389.58	500.82	29.33	1,890.41	17.62
XIV) Other Comprehensive income;					
A (i) Items that will not be reclassified to profit or loss	6.32	-	-	6.32	
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-		
B (i) Items that will be reclassified to profit or loss		-	-		
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-		
Total Comprehensive Income for the period (Comprising profit/loss) and other Comprehensive Income for the period (XIII-XIV)	1,395.91	500.82	29.33	1,896.73	17.62
XVI) Earnings per Equity Shares					
1) Basic	2.15	0.77	0.05	2.92	0.03
2) Diluted	2.11	0.76	0.05	2.87	0.03



For and on Behalf of the Board
Fischer Medical Ventures Limited
 (formerly known as Fischer Chemic Limited)

Ravindran Govindan
 Chairman & Managing Director
 DIN: 03137661

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

Consolidated Cash Flow Statement for the half year ended 30th Sep 2025

(Amount in lakhs)

PARTICULARS	For the half year ended 30-09-2025	For the half year ended 30-09-2024
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax	2,767.71	28.62
<u>Adjustment for:-</u>		
Finance Cost	158.86	17.37
Depreciation	128.34	31.13
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	3,054.91	77.12
Adjustment for:-		
(Increase)/decrease inventories	391.53	-1,364.17
(Increase)/decrease Trade and other receivables	-8,620.11	-5,288.46
Increase/(decrease) Trade Payables	2,210.44	5,205.60
Increase/(decrease) Other Financial Current Liabilities	155.61	-25.33
Increase/(decrease) Other Current Liabilities	387.53	100.57
(Increase)/decrease Others current Financial Assets	-2,124.86	-513.40
(Increase)/decrease Others Non Current Assets	-897.21	-
(Increase)/decrease Others Current Assets	-297.29	-124.09
Increase/(decrease) Non current Provisions	0.15	-
Increase/(decrease) Short term Provisions	-29.73	-
(Increase)/decrease Lease Liabilities current	-690.12	-
(Increase)/decrease Others Non Current financial Assets	-542.60	-22.46
(Increase)/decrease FCTR		7.54
CASH GENERATED FROM OPERATIONS	-7,001.76	-1,947.07
Direct Taxes Paid	52.41	-27.45
I NET CASH FLOW FROM OPERATING ACTIVITIES	-6,949.35	-1,974.52
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-831.64	-204.52
Purchase of Investments	-11,023.53	-1,049.80
Refund of Capital Advance	2,000.00	
Sale of Fixed Deposits		3,343.07
Loans & Advances Given		-6.14
II NET CASH USED IN INVESTING ACTIVITIES	-9,855.17	2,082.61
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of shares	260.96	-
(Increase)/decrease Lease Liabilities	366.51	
Proceeds/(Repaid) from Long term Borrowings	-4,671.65	
Finance cost paid and Rent Paid		-12.64
III NET CASH USED IN FINANCING ACTIVITIES	-4,044.17	-12.64
IV NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	-20,848.69	95.45
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	25,135.66	94.83
less - CASH & CASH EQUIVALENTS ACQUIRED FROM SUBSIDIARIES		
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	4,286.96	190.28



**For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)**

**Ravindran Govindan
Chairman & Managing Director
DIN: 03137661**

ANNEXURE – 2

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	MR. CHAN SING EN
DIN	11300541
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Mr. Chan Sing En (DIN: 11300541), as an Additional Non-Executive Independent Director of the Company
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/reappointment	Appointment of Mr, Chan Sing En (DIN: 11300541), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from October 28, 2025, subject to the approval of Shareholders.
Term of appointment/reappointment;	5 years
Brief profile (in case of appointment)	<p>Mr. Chan Sing En is a dynamic investment professional with over three decades of experience spanning Southeast Asia and Australia. He has built a distinguished career in private equity, corporate finance, and operational turnarounds, consistently driving growth and value creation across diverse industries. His deep understanding of financial structuring and market strategy has enabled numerous successful business revitalizations and investor partnerships.</p> <p>As Principal and Director of SovCapital Pte Ltd, Singapore, Mr. Chan leads strategic investment and restructuring initiatives for both private and public companies. He specializes in reverse takeovers, capital raising, and pre-IPO consultancy, offering seasoned guidance to founders and executives. His leadership is marked by a hands-on approach that combines strategic foresight with operational precision.</p> <p>In addition, Mr. Chan serves on the advisory board of FTAG Investment Bank in Malaysia, contributing to high-profile corporate finance transactions and cross-border deals, including the NASDAQ listing of a global supercar brand. A graduate of Pepperdine University, USA, with a degree in Business Administration, he continues to bring financial acumen, boardroom experience, and visionary leadership to every engagement.</p>
Disclosure of relationships between Directors	Mr. Chan Sing En is not related to any other Director of the Company.
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/ML/2018/24 dated June 20, 2018.	Mr. Chan Sing En is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority

ANNEXURE – 3

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	TAN SRI DATO' DR. SYED JALALUDIN
DIN	11336135
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Appointment of Dr. Syed Jalaludin En (DIN: 11336135), as an Additional Non-Executive Independent Director of the Company
Date of appointment/re-appointment/cessation (as applicable) & term of appointment/reappointment	Appointment of Dr. Syed Jalaludin (DIN: 11336135), as an Additional Non-Executive Independent Director of the Company, not liable to retire by rotation, for a first term of five consecutive years effective from the date of the approval of Shareholders.
Term of appointment/reappointment;	5 years
Brief profile (in case of appointment)	<p>Tan Sri Dato' Dr. Syed Jalaludin, aged 81 years, is a distinguished academician and visionary leader with over five decades of contribution to Malaysia's higher education, corporate, and public sectors. A PhD graduate from the University of London, he has held numerous pivotal roles including Vice Chancellor of Universiti Putra Malaysia (UPM), Chancellor of Taylor's University, and Chairman of the Board of Directors at Asia e University. His leadership was instrumental in transforming UPM into a premier institution of higher learning and research.</p> <p>Beyond academia, Tan Sri Dato' Dr. Syed Jalaludin has made a significant impact in the corporate sphere, serving as Chairman and Independent Director across major corporations such as PETRON Berhad, Bank Rakyat, and Bioalpha Holdings Berhad. His visionary guidance has driven growth, innovation, and governance excellence in both public and private enterprises, while also advancing Malaysia's position in the global halal industry through his chairmanship at the Halal Industry Development Corporation.</p> <p>He is a Fellow of the Academy of Sciences Malaysia (FASc) and the recipient of numerous national and international honours, including the Panglima Setia Mahkota (P.S.M.) conferred by His Majesty, the Yang di-Pertuan Agong, carrying the title Tan Sri. His lifelong dedication to science, education, and nation-building continues to inspire academic and business communities alike.</p>
Disclosure of relationships between Directors	Dr. Syed Jalaludin is not related to any other Director of the Company.
Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSE/ML/2018/24 dated June 20, 2018.	Dr. Syed Jalaludin is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority
